PMID- 22040190
OWN - NLM
STAT- MEDLINE
DCOM- 20120301
LR  - 20211020
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 21
IP  - 5
DP  - 2011 Oct
TI  - Subjective effects, misuse, and adverse effects of osmotic-release 
      methylphenidate treatment in adolescent substance abusers with 
      attention-deficit/hyperactivity disorder.
PG  - 455-63
LID - 10.1089/cap.2011.0014 [doi]
AB  - OBJECTIVE: Psychostimulants are effective treatments for 
      attention-deficit/hyperactivity disorder (ADHD) but may be associated with 
      euphoric effects, misuse/diversion, and adverse effects. These risks are 
      perceived by some clinicians to be greater in substance-abusing adolescents 
      relative to non-substance-abusing adults. The present study evaluates the 
      subjective effects, misuse/diversion, and adverse effects associated with the use 
      of osmotic-release oral system methylphenidate (OROS-MPH), relative to placebo, 
      for treating ADHD in adolescents with a substance use disorder (SUD) as a 
      function of substance use severity and compared these risks with those associated 
      with the treatment of ADHD in adults without a non-nicotine SUD. METHOD: Datasets 
      from two randomized placebo-controlled trials of OROS-MPH for treating ADHD, one 
      conducted with 303 adolescents (13-18) with at least one non-nicotine SUD and one 
      with 255 adult smokers (18-55), were analyzed. Outcome measures included the 
      Massachusetts General Hospital Liking Scale, self-reported medication compliance, 
      pill counts, and adverse events (AEs). RESULTS: Euphoric effects and 
      misuse/diversion of OROS-MPH were not significantly affected by substance use 
      severity. The euphoric effects of OROS-MPH did not significantly differ between 
      the adolescent and adult samples. Adults rated OROS-MPH as more effective in 
      treating ADHD, whereas adolescents reported feeling more depressed when taking 
      OROS-MPH. The adolescents lost more pills relative to the adults regardless of 
      treatment condition, which suggests the importance of careful medication 
      monitoring. Higher baseline use of alcohol and cannabis was associated with an 
      increased risk of experiencing a treatment-related AE in OROS-MPH, but baseline 
      use did not increase the risk of serious AEs or of any particular category of AE 
      and the adolescents did not experience more treatment-related AEs relative to the 
      adults. CONCLUSIONS: With good monitoring, and in the context of substance abuse 
      treatment, OROS-MPH can be safely used in adolescents with an SUD despite 
      non-abstinence.
FAU - Winhusen, Theresa M
AU  - Winhusen TM
AD  - Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati 
      College of Medicine, Cincinnati, Ohio 45220, USA. winhusen@carc.uc.edu
FAU - Lewis, Daniel F
AU  - Lewis DF
FAU - Riggs, Paula D
AU  - Riggs PD
FAU - Davies, Robert D
AU  - Davies RD
FAU - Adler, Lenard A
AU  - Adler LA
FAU - Sonne, Susan
AU  - Sonne S
FAU - Somoza, Eugene C
AU  - Somoza EC
LA  - eng
GR  - K12 DA000357/DA/NIDA NIH HHS/United States
GR  - K12 DA 000357/DA/NIDA NIH HHS/United States
GR  - U10 DA012732/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Central Nervous System Stimulants)
RN  - 207ZZ9QZ49 (Methylphenidate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy
MH  - Central Nervous System Stimulants/*administration & dosage
MH  - Humans
MH  - Methylphenidate/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Osmosis
MH  - Smoking
MH  - Substance-Related Disorders/*drug therapy
PMC - PMC3243465
EDAT- 2011/11/02 06:00
MHDA- 2012/03/02 06:00
PMCR- 2012/10/01
CRDT- 2011/11/02 06:00
PHST- 2011/11/02 06:00 [entrez]
PHST- 2011/11/02 06:00 [pubmed]
PHST- 2012/03/02 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - 10.1089/cap.2011.0014 [pii]
AID - 10.1089/cap.2011.0014 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2011 Oct;21(5):455-63. doi: 
      10.1089/cap.2011.0014.